Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Mitchell

Gastroenterology Richmond, VA Medical Doctor

NPI 1639252109 CMS profile 255431

7605 Forest Ave Ste 211, Richmond, VA 23229

Open in the dashboard

General payments

$7,189

413 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Mitchell of Richmond, VA is reported in the CMS Open Payments database as having received $7,189 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,474 73
2024 General $913 56
2023 General $1,059 68
2022 General $1,984 91
2021 General $970 75
2020 General $294 14
2019 General $495 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Mitchell
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Robert Mitchell were reported at $1,474. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Robert Mitchell Gastroenterology median Middle half National median
2019 $495 $417 $126–$1,100 $163
2020 $294 $224 $74–$624 $114
2021 $970 $352 $106–$1,054 $132
2022 $1,984 $448 $129–$1,270 $149
2023 $1,059 $533 $150–$1,390 $160
2024 $913 $605 $160–$1,606 $164
2025 $1,474 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,604 138 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,293 84 payments
  3. Janssen Biotech, Inc. $881 27 payments
  4. ERBE USA Inc $521 2 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $505 39 payments
  6. QOL Medical, LLC $343 21 payments
  7. Genzyme Corporation $317 16 payments
  8. Braintree Laboratories, Inc. $205 13 payments
  9. Daiichi Sankyo Inc. $205 10 payments
  10. Pfizer Inc. $147 4 payments
  11. Other $1,168 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,015 403 payments
  2. Gift $138 8 payments
  3. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $1,026 60 payments
  2. RINVOQ $763 63 payments
  3. STELARA $611 16 payments
  4. ERBE $505 1 payment
  5. TREMFYA $398 13 payments
  6. ENTYVIO $381 27 payments
  7. SKYRIZI $347 20 payments
  8. LINZESS $334 26 payments
  9. DUPIXENT $317 16 payments
  10. HUMIRA $317 31 payments
  11. Other $3,015 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,841

Median for Gastroenterology: 569

Drug cost

$1,599,269

Median for Gastroenterology: $104,976

Branded share of claims

36.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $538,495
Stelara Ustekinumab Brand 12 $321,024
Skyrizi On-Body Risankizumab-Rzaa Brand 12 $244,844
Creon Lipase/Protease/Amylase Brand 43 $242,659
Humira Pen Adalimumab Brand 12 $83,496
Xifaxan Rifaximin Brand 12 $50,405
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 308 $20,816
Mesalamine Generic 29 $19,634
Budesonide Ec Budesonide Brand 39 $12,979
Mesalamine Er Mesalamine Brand 38 $10,539

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$830,382

Of which drugs: $712,480

Medicare patients

722

Average age 74

Services billed

42,021

418 women, 304 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 49%
Ischemic heart disease 28%
Diabetes 25%
Osteoporosis 19%
Atrial fibrillation 18%
Cancer 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 12 18,900 $330,047
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 13 3,480 $86,486
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 13 368 $84

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sucraid
  • QOL Medical, LLC $104
$104 — —
DUPIXENT
  • GENZYME CORPORATION $90
$90 — —
TREMFYA
  • Janssen Biotech, Inc. $90
$90 — —
RINVOQ
  • AbbVie, Inc. $79
$79 — —
SKYRIZI
  • AbbVie, Inc. $77
$77 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record